
Scientists pinpoint natural remedy that could help treat diabetes without the need for drugs - and it costs just 55p
Ginger—also known as zingiber officinale—has been used for decades to treat everything from morning sickness to arthritis thanks to its anti-inflammatory properties.
But now researchers say ginger supplements could help manage type two diabetes, significantly lowering blood glucose levels and reducing the risk of heart disease, kidney failure and stroke.
Often referred to as the 'silent killer', diabetes is becoming a growing problem across the UK, with 3.6million people estimated to be living with type two diabetes in England alone.
Type two diabetes occurs when the body does not make enough insulin, or the insulin it does make doesn't work properly.
This causes an increase in blood sugar levels, which left untreated can be life-threatening.
Unhealthy lifestyle factors can increase the risk of developing the condition, with rising obesity levels thought to be behind the sharp increase in cases.
In the current study, US researchers reviewed five meta analyses of previous studies to examine whether ginger can effectively treat inflammation, oxidative stress—a precursor for a number of serious diseases including cancer—morning sickness and type two diabetes.
Researchers found that ginger had functional benefits across all four areas, leading to significant reductions in key inflammatory markers and reduced nausea and vomiting in pregnancy.
But most intriguingly, they also found ginger to have a powerful effect on glycemic control, meaning patients could better tolerate carbohydrates which are known to increase blood sugar levels.
Researchers also found that ginger increases GLUT-4 protein levels in the body, helping muscles and fat cells absorb glucose from the blood to keep blood sugar levels steady.
Finally, they concluded that the lowering of a long-term blood sugar marker—called HbA1c shows that ginger could have lasting effects, making it an effective natural therapy for diabetes sufferers.
Notably, the typical dose of ginger used in these studies ranged from around one to three grams per day, which researchers said could have interfered with the results, making it difficult to ascertain exactly how much ginger a patient would need to manage symptoms.
They are now looking to conduct more large-scale trials to define optimal dosing and the best way to incorporate the powerful active ingredient into a patient's diet.
The findings come following alarming new research which found that people diagnosed with type 2 diabetes before the age of 40 have a death rate four times higher than the general UK population.
People diagnosed before the age of 40 also had a higher rate of diabetes-related complications, particularly microvascular disease such as eye damage and kidney failure.
And a lower age of diagnosis was also associated with persistently poorer blood sugar control.
Professor Amanda Adler, co-author of the study, said: 'Over the past 30 years, the number of young adults diagnosed with type 2 diabetes has increased markedly worldwide.
'Evidence to date suggests that younger-onset type 2 diabetes, characterised by earlier and longer exposure to high levels of blood glucose, may be more aggressive than later onset disease.'
This might include faster deterioration in beta-cell function - the cells in the pancreas that produce and release insulin - and a greater risk of complications such as cardiovascular and kidney disease.
Lead author Dr Beryl Lin said: 'Our data supports the need to proactively identify young adults with type 2 diabetes and provide high-quality care over their lifetimes.
'We urgently need clinical trials focused on young people to develop tailored treatments which prevent or delay complications, like kidney and heart disease, and crucially, reduce the risk of premature death.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
35 minutes ago
- Daily Mail
Physiotherapist reveals why you should NEVER cross your legs on a flight
It can be difficult to get comfortable during plane journeys, with small seats and little leg room there is often not much room for movement. Many passengers cross their legs on flights, but AXA Health physiotherapist Bethany Tomlinson has warned against the common seating position. According to research, more than one in 10 adults in the UK experience joint issues. However, this pain could be worsened by long periods of inactivity sitting on aeroplanes. Bethany explains the risks that can come with sitting cross-legged during a flight. She warns: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' Instead, the expert advises keeping legs elevated and choosing different relaxing positions. 'If there's a footrest under the seat in front of you, use this to keep your legs slightly elevated,' she adds. 'Make sure to relax your shoulders and support your back by sitting back into the plane seat whilst you wait.' To the millions of Brits jetting off this summer, Bethany urges travellers to prepare for the journey to avoid causing strain on joints. One in three Brits experience stiffness in their knees, and lack of movement or staying in the same position can only worsen this. Bethany says: 'Catching flights this summer could turn into an endurance test for our joints, so prepare for every flight like it could be long-haul. 'Knowing how to position your body and doing exercises when seated to keep your joints moving is essential.' Another way to ease joint discomfort is by standing in a certain position, Bethany explains. She adds: 'When standing up, shift weight between your feet, keep knees slightly bent and do light stretches to avoid too much pressure on your lower body.' For longer flights, Bethany shares what routine passengers should keep to in order to ensure their joints are healthy. Bethany warns passengers: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' (stock) 'Flyers need to move their body every 1-2 hours on flights to keep joints mobilised. 'Being in the same position for hours can lead to stiff and swollen joints, particularly the knees, ankles and hips. 'Seated exercises whilst in the air will help boost circulation, and reduce the risk of DVT, a common type of blood clot that can form during long periods of sitting.' The physiotherapist shared a range of mobilising exercises that passengers can easily do from their plane seat, including neck stretches, shoulder rolls and knee hugs.


The Independent
an hour ago
- The Independent
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.


The Independent
2 hours ago
- The Independent
New advanced bladder cancer treatment can ‘double chances of survival'
A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.